University Of Dundee;University Court of The University of St Andrews
发明人:
申请号：
EP18765992.5
公开号：
EP3675961A1
申请日:
2018.08.30
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
A method of treating a neurological disorder comprising administering a leptin peptide fragment comprising amino acids located within the region of amino acids 116 – 125 of leptin is disclosed. The leptin peptide fragment preferably comprises up to 30 amino acids, and/or wherein the leptin peptide fragment comprises one or more amino acids located between amino acids 116 – 122 of leptin, for example the sequence X1CX2LPX3X4 wherein X1 is selected from G or S； X2 is selected from S, H or P； X3 is selected from Q, H, W, L, P or R and X4 is selected from T, A, or V (SEQ ID NO:14) or the sequence SCHLPWASGL (SEQ ID NO:22). The neurological disorder can include those which would benefit from treatment through cognitive enhancement and/or neuroprotection, such as age-associated memory impairment or loss, mild cognitive impairment, and Alzheimer's disease, and can include Parkinson's disease, frontotemporal dementia, progressive supranuclear palsy, Pick's disease, corticobasal degeneration, alcoholic dementia, (DLB) dementia with Lewy bodies, Picks' disease, thalamic dementia, hippocampal sclerosis, Hallervorden-Spatz, multiple system atrophy, tauopathies, subacute aterioscleroitic encephalopathy (Binswanger's disease), amyloid angiopathy, vasculitis, prion diseases, and paraneoplastic syndromes. The invention also includes a pharmaceutical formulation for this method, which can include the peptide in the form of a cyclic peptide or a peptide conjugate.
